Abstract 29P
Background
Immune checkpoint inhibitors (ICI) will become the new standard therapy for early muscle-invasive bladder cancer (MIBC). Despite high response rates, a significant proportion of patients still dies from lethal relapse. Moreover, validated biomarkers to ICI are lacking. Here, we evaluated systemic inflammatory index (SII) and platelet-to-lymphocyte ratio (PLR) as prognostic biomarkers for MIBC patients in the AURA trial.
Methods
AURA is a prospective phase 2 trial (NCT03674424) evaluating neoadjuvant avelumab alone or in combination with different chemotherapy regimens according to cisplatin eligibility. Pre-treatment SII, deriving from the formula (neutrophils x platelets)/lymphocytes, and baseline PLR, absolute platelets to lymphocytes ratio, were categorized as low < median or high ≥ median. Associations of biomarkers with pathological responses, event-free survival (EFS) and overall survival (OS) were measured using Fisher’s exact test, Kaplan-Meier and Cox regression methods.
Results
Low SII showed a significant correlation (p=0.002) with pathological complete response (pCR), longer EFS (median: NR vs 26 months, HR = 0.42) and longer OS (median: NR vs 40 months, HR = 0.50) and a trend for downstaging ( Low pre-treatment SII, witnessing low level of systemic inflammation, was significantly associated with response to neoadjuvant chemo-immunotherapy as well as with longer survival, suggesting that SII could be used as a predictive biomarker for MIBC treatment tailoring, if further validated. In contrast, baseline low PLR was not correlated with better outcomes, suggesting that the platelet count alone is not strong enough to reflect the systemic inflammation. NCT03674424. Institut Jules Bordet and FNRS. Merck KGaA, Darmstadt, Germany. J. Blanc: Financial Interests, Institutional, Advisory Role: Merck; Financial Interests, Institutional, Invited Speaker: BMS; Financial Interests, Personal, Other, Travel support: Ipsen, AstraZeneca, Merck. N. Martinez Chanza: Financial Interests, Institutional, Speaker, Consultant, Advisor: Merck. A. Carnot: Financial Interests, Personal, Advisory Board: MSD Oncology, Janssen Oncology; Financial Interests, Personal, Invited Speaker: Astellas Pharma. P. Barthelemy: Financial Interests, Personal, Advisory Board: BMS, MSD, Merck, Pfizer, Ipsen, Bayer, Janssen Cilag, Astellas, Novartis, Amgen, Gilead; Financial Interests, Personal, Invited Speaker: AstraZeneca. C. Sotiriou: Financial Interests, Institutional, Advisory Board: Astellas, Seattle Genetics, Amgen, Merck & Co; Financial Interests, Personal, Advisory Board: Cepheid; Financial Interests, Institutional, Other, Travel: Roche; Financial Interests, Personal, Other, Travel: Pfizer; Financial Interests, Institutional, Invited Speaker: Exact Sciences; Financial Interests, Personal, Invited Speaker: Prime Oncology; Financial Interests, Personal, Advisory Board, Stock options: Signatur Biosciences; Financial Interests, Personal, Stocks/Shares, Stock: Signatur Biosciences. All other authors have declared no conflicts of interest.Conclusions
Clinical trial identification
Legal entity responsible for the study
Funding
Disclosure
Resources from the same session
64P - Gene-editing of T cells to provide resistance against macrophage-mediated suppression: setting up an in vitro model
Presenter: Rui Coelho
Session: Poster Display session
Resources:
Abstract
68P - Real-world outcomes of nivolumab and/or ipilimumab in patients with stage III-IV melanoma, MELIOR study
Presenter: Ainara Soria Rivas
Session: Poster Display session
Resources:
Abstract
69P - Dose-dependent detrimental effect of proton pump inhibitors (PPIs) on clinical outcomes from immune checkpoint inhibitors (ICI) in patients (pts) with solid tumors
Presenter: elena speziale
Session: Poster Display session
Resources:
Abstract
70P - Efficacy of PD-1 blockade plus chemotherapy in patients with oncogenic-driven non-small cell lung cancer
Presenter: Haowei Wang
Session: Poster Display session
Resources:
Abstract
71P - Discontinuation of immune checkpoint inhibitors for reasons other than disease progression and the impact on relapse and survival of advanced melanoma patients: A systematic review and meta-analysis
Presenter: Konstantinos Lallas
Session: Poster Display session
Resources:
Abstract
72P - Concurrent local therapy (CLT) extends clinical benefit of tebentafusp (tebe) in metastatic uveal melanoma (mUM) patients (pts)
Presenter: Tristan Lim
Session: Poster Display session
Resources:
Abstract
73P - Impact of Assessment-to-Treatment Interval on the Predictive Value of PD-L1 Expression in Melanoma
Presenter: Cecilie Vestergaard
Session: Poster Display session
Resources:
Abstract
74P - Real-world impact of adjuvant anti-PD-1 therapy on survival in Danish resected stage III melanoma patients
Presenter: Marie Weitemeyer
Session: Poster Display session
Resources:
Abstract
75P - Real-world data of adebrelimab in the first-line treatment of patients with small cell lung cancer
Presenter: Yong Song
Session: Poster Display session
Resources:
Abstract
76P - Fixed 2-year vs. continuous duration immune checkpoint inhibitors in patients diagnosed with advanced cancer: to continue or not to continue?
Presenter: Miles Smith
Session: Poster Display session
Resources:
Abstract